The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC
Titel:
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC
Auteur:
Rodríguez-Abreu, D. Cobo, M. García-Román, S. Viteri-Ramírez, S. Jordana-Ariza, N. García-Peláez, B. Reguart, N. Aguilar, A. Codony-Servat, J. Drozdowskyj, A. Molina-Vila, M.A. d'Hondt, E. Rosell, R.